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ages mentioned below were not measured with this instrument due to lack of hands
on experience by the author. TreeAge ProSuite was included as a gold standard com-
parator forHE. A Linkert scale (1 to 5)was used to grade each item.RESULTS: Thirteen
packages were found and considered in this review. Among the best software (in-
cluded two or three characteristics of the selection criteria) suitable for HE modeling
were AnyLogic, Arena, SAS Simulation Studio, Simio, Simul8 and TreeAge. Average
grades (ordered from less expensive tomost expensive)were as follows: Simul8-Basic,
3.89; TreeAge ProSuite, 3.07; Arena-Basic, 3.00; Simul8-Professional, 4.43.
CONCLUSIONS: This work tried to create a list of items to objectively measure the
characteristics of HE modeling software. At this point results of the graded packages
represent theviewsof theauthor. This instrumentmaybeauseful toolwhendeciding
between different packages to buy. Future work is required for this instrument to be
assessed by other modeling experts.
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OBJECTIVES: To evaluate an online calculator for analyzing and scoring health
intervention options using the analytic hierarchy process (AHP).METHODS:Aweb-
based calculator was developed that generates priority scores using the Analytic
Hierarchy Process as well as various AHP statistics and graphs. AHP is designed to
assist in decision-making situations involving multiple attributes by making judg-
ments about the relative importance of key attributes and then specifying a pref-
erence for each decision alternative on each attribute. The web-based software is
freely available at: www.healthstrategy.com (HDS). The tool was compared to an
MS Excel calculator from K. Teknomo which can be downloaded from: http://peo-
ple.revoledu.com/kardi/tutorial/AHP. These two software options were evaluated
against results from a published health economics paper from Nuijten and Kosa
that utilized AHP on three antidepressant choices around the threemain factors of
budget impact, therapeutic value, and cost effectiveness. RESULTS: The published
paper results compared with the Teknomo and HDS calculators were as follows on
factor weights: Budget Impact (0.28, 0.28, 0.28), Cost Effectiveness (0.07, 0.07, 0.07),
Therapeutic Value (0.65, 0.64, 0.64). On overall score (composite weights) the pub-
lished paper compared with the Teknomo and HDS calculators as follows: New
Drug (0.49, 0.56, 0.56), SSRI (0.26, 0.18, 0.18), TCA (0.25, 0.26, 0.26). CONCLUSIONS:
Both software approaches provided basic statistics and graphs often found in AHP
reports. For basic scoring, the HealthStrategy and Teknomo approaches provided
similar results, but differed somewhat from the published paper that used addi-
tional sub-factors on some attributes. For future research, additional datasets
should be explored, sensitivity analyses should be performed on key variables, and
comparisons should be made with more comprehensive software and multi-attri-
bute utility approaches.
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OBJECTIVES: Patient non-adherence to prescribed therapies has been shown to be
associated with worse health outcomes. However, it is unclear the extent to which
adherence varies as a function of the condition versus the patient. The aim of this
study was to investigate the consistency of adherence scores across the costliest
chronic conditions in the U.S.METHODS: Data from the 2010 U.S. National Health
and Wellness Survey (NHWS) were used. Included for analysis were only those
patients (N32,636) who reported using a medication for their asthma, pain, con-
gestive heart failure (CHF), COPD, diabetes, hypertension, depression, bipolar dis-
order, peripheral vascular disease (PVD), transient ischemic attack (TIA), or stroke.
Adherence, measured using the four-item Morisky Medication Adherence Scale
(MMAS), was assessed separately for each condition. Health utilities were also
assessed using the SF-12v2. RESULTS: Among patients taking prescription medi-
cation for asthma (n4,786), pain (n8,984), CHF (n905), COPD (n1,664), diabetes
(n7,065), hypertension (n19,475), depression (n7,850), bipolar disorder
(n1,425), PVD (n163), TIA (n437), or stroke (n507), 48.9% were male, 79.3%
were white, and mean age was 54.9 years (SD15.3). Across all conditions, high
internal consistency was observed for total MMAS scores (Cronbach’s a0.97) and
all MMAS items (“careless about taking medications”, a0.97; “stop taking medi-
cations when feeling better”, a0.94; “stop taking medications when feeling
worse”, a0.96; and “forgetting to take medications”, a0.97). Number of respon-
dents sharing any two conditions ranged from n9 to n4563, yet MMAS total
score correlations across any two conditions were all significant, ranging from
r0.41 to r1.00.With the exception of pain, non-adherencewithin each condition
was associated with lower health utilities (though not always significantly:
r0.02 to r0.12).CONCLUSIONS: The results suggest that adherence is a stable
construct, consistent from condition to condition for each patient. Non-adherence
on one therapy may be an indicator of non-adherence on another therapy.
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OBJECTIVES: Previous researchers (Ren, 1999) have used a 5-item shortened ver-
sion of the Medical Outcomes Study Social Support Scale (MOS-SSS; Sherborne,
1991), but the measurement properties of this brief measure have not been estab-
lished. We filled this gap by evaluating the psychometric properties of a 5-item
perceived social support instrument (the SS-5) and testing equivalence between
paper and web-based administration modes.METHODS: The SS-5 and other ques-
tionnaire measures were administered to a sample of adults recruited through
newspaper and web-based advertisements in 8 US cities. Participants were ran-
domized to complete the SS-5 on either paper or computerized format followed by
a one-week retest. The intraclass correlation coefficient (ICC) was calculated to
assess reproducibility of the SS-5 and equivalence between administrationmodes.
Cronbach’s alpha was calculated to assess internal consistency. To assess known
groups’ validity, differences in SS-5 scores between marital status/living arrange-
ment groups and (separately), trichotomous groupings of a validated measure of
dispositional optimism, the Life Orientation Test (LOT-R), were assessedwith anal-
ysis of variance (ANOVA)models. RESULTS:Of the 258 participants that completed
the baseline assessment, 251 (97%) completed the retest. Mean age of participants
was 48.6 years, 61% were female, and 71% were Caucasian. Participants included
44% married or living with a partner; 24% had never been married. The mean SS-5
scorewas 17.34.9, and the ICC between paper andweb-basedwas 0.89. Reproduc-
ibility was strong (ICC0.92), and the instrument was internally consistent (al-
pha0.88). The SS-5 significantly discriminated between participants living with a
partner and those living alone (means: 19.1 vs. 15.9; p0.001) and tertiles of the
LOT-R. The correlation of SS-5 scores to the full MOS-SSS was 0.91. CONCLUSIONS:
The SS-5 was observed to have adequate reproducibility and internal consistency;
and demonstrated appropriate known groups validity. Equivalence between paper
and web-based administration was demonstrated.
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OBJECTIVES: A self-administered questionnaire was developed to evaluate health
related quality of life (HRQoL) with over-the-counter (OTC) product use and HRQL
with OTC product use associated adverse drug events (ADRs). Validity and reliabil-
ity was assessed to determine psychometric properties of these new instruments.
METHODS: The questionnaire was developed as part of a cross sectional study in
an elderly population and included content based on existing literature and dis-
cussionswith expert panel. HRQoLOTC product use scale (9 items) andHRQoLOTC
ADR scale (9 items) was measured using a 5-point Likert scale (strongly agree to
strongly disagree). The questionnaire was tested on a pilot sample to evaluate
legibility, response burden, and comprehension. Seniors residing in retirement
homes or visiting senior community centers and using OTC products participated.
Reliability was evaluated on the basis of internal consistency. Concurrent validity
was evaluated by comparing scores obtainedwith an existing general health status
measure (GHS). Data were collected and analyzed using SAS v9.2. RESULTS: A total
of 157 seniors completed the survey yielding a response rate of 66.5%. The mean
age of the sample was 75.1(4.7) years with majority being male (56.2%) and white
(67.5%). Of the total sample, 22.9% had an adverse event due to OTC use. The
reliability coefficient was very high for the two scales, namely, HRQL OTC product
use scale (0.95) and HRQoL OTC ADR scale (0.92), with mean summary scores of
3.60.8 and 2.50.6, respectively. The GHS measure was significantly correlated
with HRQoL OTC product use (r0.3, p0.0001) and HRQoL OTC ADR (r 0.5,
p0.01) scores. In addition, both scales were significantly correlated with each
other (r0.7, p0.0001). CONCLUSIONS: Both scales exhibit excellent reliability
and evidence of validity. Further, assessment using other products and different
populations would help increase generalizability of these instruments.
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OBJECTIVES: There is some debate about whether utilities can exceed 1.0. This
assumption has important ramifications regarding which statistical methods are
appropriate. It is convention that utilities are anchored at 0.0 (death) and 1.0 (full
health). The descriptive health state corresponding to ‘full health’ differs across
instruments. The objective of this research is to examine the extent to which the
value for ‘full health’ differs between the SF-6D and the EQ-5D and to explore the
existence of a ceiling effect for utilities.METHODS: The 2000-2003 Medical Expen-
diture Panel Survey was used to estimate predicted SF-6D and EQ-5D (UK) scores
using Tobit, CLADandOLS regressions. EQ-5D (and SF-6D) scoreswere regressed on
SF-12 scores and sociodemographic characteristics. The regression equationswere
then used to predict EQ-5D and SF-6D scores. The two series of predicted scores
were compared to examine ceiling and floor effects. RESULTS: 47% of individuals
had a score of 1.0 on the EQ-5D and only 7% on the SF-6D. The SF-6D exhibited
significant floor effects with the lowest value at 0.344 compared to 0.594 for the
EQ-5D. Based on the Tobit predicted scores, a value of 1.0 on the SF-6D corre-
sponded to a value of 1.2 on the EQ-5D. This result suggests that a large portion of
the 46% of individuals with a score of 1.0 on the EQ-5D would actually have utility
scores greater than 1.0 on a scale without such a pronounced ceiling effect. Like-
wise a 0.34 on the SF-6D corresponded to 0.03 on the EQ-5D, suggesting a floor effect
for the SF-6D. CONCLUSIONS: Statistical estimation should incorporate censored
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